NLS Pharmaceutics AG (NLSP )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NLSP
- Company NLS Pharmaceutics AG
- Price $3.29
- Changes Percentage 3.46
- Change 0.11
- Day Low $3.11
- Day High $3.55
- Year High $29.08
- Year Low $3
- Market Cap $8,134,328
- Price Avg 50 EMA (D) $4.66
- Price Avg 200 EMA (D) $7.59
- Exchange NASDAQ
- Volume 66,232
- Average Volume 213,254
- Open $3.11
- Previous Close $3.18
- EPS -6.74
- PE -0.49
- Earnings Announcement 2025-02-26 12:00:00
- Shares Outstanding $2,472,440
Company brief: NLS PHARMACEUTICS AG (NLSP )
- Healthcare
- Biotechnology
- Mr. Alexander Zwyer M.B.A.
- https://nlspharma.com
- CH
- N/A
- 01-29-2021
- CH0523961370
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.